Epimune GmbH is a diagnostic company pioneering epigenetic immune cell quantification from a drop of blood.
Immune cell enumeration is crucial for early detection and monitoring of patients with immune cell disorders, including primary immunodeficiency, HIV infection, cancer, autoimmunity, autoinflammation and immunosuppression. Standard clinical practice calls for laboratory analysis of fresh blood samples by flow cytometry within 24 h after a venous blood draw.
Using dried blood spots (DBS) and proprietary real-time PCR-based test kits, Epimune enables clinical applications where fresh blood samples of sufficient quality and quantity for flow cytometric analysis are difficult or impossible to obtain – e.g. patient management in regions of limited laboratory and fresh blood transport infrastructure, at-home blood sampling, near-patient testing and newborn screening.
Epimune builds on technology developed over 15 years under the roof of Epiontis/A Precision for Medicine company and exclusively licensed to Epimune for in-vitro diagnostic (IVD) applications.